Product Description
A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate. Enzastaurin hydrochloride blocks certain cell signaling pathways, and may prevent the growth of new blood vessels that tumors need to grow. It is a type of serine threonine kinase inhibitor and a type of antiangiogenesis agent. Also called LY317615. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/enzastaurin-hydrochloride)
Mechanisms of Action: PKC Beta Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Ehlers-Danlos SyndromeFast Track - GlioblastomaOrphan Drug - Ehlers-Danlos Syndrome *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, El Salvador, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Ehlers-Danlos Syndrome|Environmental Hypersensitivity|Glioblastoma|Peanut Hypersensitivity
Phase 2: Hyperpigmentation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05511948 |
CT-212 | P2 |
Completed |
Hyperpigmentation |
2023-03-07 |
12% |
2023-10-26 |
Primary Completion Date|Primary Endpoints |
2021-006574-23 |
PREVEnt (Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome Trial) | P3 |
Active, not recruiting |
Ehlers-Danlos Syndrome |
2025-08-30 |
2025-05-06 |
Treatments |
|
NCT03776071 |
DB102-01 | P3 |
Completed |
Glioblastoma |
2024-02-29 |
31% |
2024-04-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT03292484 |
ARC008 | P3 |
Completed |
Environmental Hypersensitivity|Peanut Hypersensitivity |
2023-04-27 |
45% |
2024-12-20 |
Primary Endpoints|Start Date|Treatments |